Current diagnosis and therapy of esophageal carcinoma;Aktuelle diagnostik und therapie des ösophaguskarzinoms

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 7, 2004, Pages 615-621

  Muhr Wilkenshoff F ^a   Stahl, M ^b   Faiss, S ^a   Zeitz, M ^a   Scherübl, Hans ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Chemoradiation; Chemotherapy; Esophagectomy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN; NEDAPLATIN; OXALIPLATIN; PACLITAXEL;

ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL EXAMINATION; DIAGNOSTIC IMAGING; DRUG CHOICE; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; HUMAN; MULTIMODALITY CANCER THERAPY; REVIEW; SQUAMOUS CELL CARCINOMA; STENT; TREATMENT INDICATION;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FOLLOW-UP STUDIES; GERMANY; HUMANS; INCIDENCE; NEOADJUVANT THERAPY; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE;

EID: 3342977806     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-812790     Document Type: Review

References (56)

1. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Sem Oncol 1999; 26: 2-8
2. Bareiss D, Stabenow R, Müller R et al. Aktuelle Epidemiologie des Ösophaguskarzinoms und des Kardiakarzinoms in Deutschland. DMW 2002; 127: 1367-1374
3. Lagergren J, Bergstrom R, Lindgren A et al. The role of tobacco, snuff and alcohol use in the etiology of cancer of the esophagus and gastric cardia. Int J Cancer 2000; 85: 340-346
4. Scherübl H, von Lampe B, Faiss S et al. Screening for esophageal neoplasia in patients with head and neck cancer. Brit J Cancer 2002; 86: 239-243
5. Scherübl H, Scherer H, Hoffmeister B. Second esophageal cancers in head and neck cancer patients. N Engl J Med 2002; 346: 1416-1417
6. Scherübl H, Sutter A, Zeitz M. NSAIDs and esophageal cancer. Gastroenterology 2003; 125: 1914-1915
7. Lagergren J, Bergstrom R, Lindgren A et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831
8. Spechler SJ. Barrett's esophagus. N Engl J Med 2002; 364: 836-842
9. Hermaneck P, Sobin LH. TNM classification of malignant tumors. International Union Against Cancer, 4th ed. Berlin: Springer-Verlag, 1987
10. Rösch T. Endosonographic staging of esophageal cancer: A review of literature results. Gastrointest Endosc Clin North Am 1995; 5: 537-547
11. Vazquez-Sequeiros E, Wiersema M, Clain J et al. Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology 2003; 125: 1626-1635
12. Takashima S, Takeuchi N, Shiozaki H et al. Carcinoma of the esophagus: CT vs MR imaging in determing resectability. Am J Roentgenol 1991; 156: 297-302
13. Hulscher JBF, van Sandick JW, de Boer AG et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347: 1662-1669
14. Hölscher AH, Bollschweiler E, Schneider PM et al. Prognosis of early esophageal cancer. Cancer 1995; 76: 178-186
15. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349: 2241-2252
16. Birkmeyer J, Stukel T, Siewers A et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349: 2117-2127
17. Siewert JR, Stein HJ, Feith M et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1000 consecutive resections at a single center in the Western world. Ann Surg 2001; 234: 360-369
18. De-Ren S. Ten-year follow-up of esophageal cancer treated by radical radiation therapy. J Radiat Oncol Biol Phys 1989; 16: 329-334
19. Ell C, May A, Pech O et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barretts esophagus. Gastroenterology 2000; 118: 670-677
20. Recht A. The role of radiation therapy in treating patients with potentially resectable carcinoma of the esophagus. Chest 1995; 107: 233S-240S
21. Albertson M, Ewers SB, Widmark H et al. Evaluation of the palliative effect of radiotherapy for esophageal carcinoma. Acta Oncol 1989; 25: 267-270
22. Ajani JA. Docetaxel for gastric and esophageal cancer. Oncology (Huntingt) 2002; 16: 89-96
23. Ajani JA, Ilson DH, Daugherty K et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86: 1086-1091
24. Mühr-Wilkenshoff F, Hinkelbein W, Ohnesorge I et al. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis 2003; 18: 330-334
25. Stahl M. Chemotherapy of esophageal carcinoma. Onkologie 1999; 22: 98-104
26. Wadler S, Haynes H, Beitler JJ et al. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or locally advanced carcinoma of the esophagus. Cancer 1996; 78: 30-34
27. Polee MB, Eskens FA, van der Burg ME et al. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced esophageal cancer. Br J Cancer 2002; 86: 669-673
28. Ilson DH, Forastiere A, Arquette M et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000; 6: 316-323
29. Ilson DH, Ajani JA et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998; 16: 1826-1834
30. Garcia-Alfonso P, Guevara S, Lopez P et al. Taxol and cisplatin + 5-fluorouracil sequential in advanced esophageal cancer. Proc Am Soc Clin Oncol 1998; 17: 260a
31. Ilson DH, Saltz L, Enzinger P et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17: 3270-3275
32. Ajani JA, Baker J, Pisters PW et al. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Huntingt) 2002; 16: 16-18
33. Oettle H, Arnold D, Kern M et al. Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer. Anticancer Drugs 2002; 13: 833-838
34. Livingston R, Edwards J, Gold P. Phase II trial of irinotecan and mitomycin C in the treatment of metastatic esophageal cancer. Proc Am Soc Clin Oncol 2003; 22: 292 (abstr 1171)
35. Hoff P, Fuchs C. The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas. Semin Oncol 2003; 30: 54-61
36. Yoshioka T, Gamoh M, Shineha R et al. A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers. Intern Med 1999; 38: 844-848
37. Wong R, Malthaner RA, Zuraw L et al. Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: A practice guideline. Int J Ratiat Oncol Biol Phys 2003; 55: 930-942
38. Herskovic A, Martz K, Al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-1598
39. Walsh TN, Noonan N, Hollywood D et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-467
40. Urba SG, Orringer MB, Turrisi A et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophgeal carcinoma. J Clin Oncol 2001; 15: 305-313
41. Burmeister BH, Smithers BM, Fitzgerald L et al. A randomized phase III trial of preoperative chemoradiation followed by surgery (CR-S) versus surgery alone (S) for localized resectable cancer of the esophagus. Proc Am Soc Clin Oncol 2002; 21: 130 (abstract)
42. Meluch AA, Greco FA, Gray JR et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiotherapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 2003; 9: 251-260
43. Bedenne L, Michel P, Bouche O et al. Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc Am Soc Clin Oncol 2002; 21: 130 (abstract)
44. Stahl M, Wilke H, Walz MK et al. Randomized phase III trial in locally advanced squamous cell carcinoma (SCC) of the esophagus: Chemoradiation with and without surgery. Proc Am Soc Clin Oncol 2003; 22: 250 (abstract)
45. Bidoli P, Bajetta E, Stani SC et al. Ten year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus. Cancer 2002; 94: 352-361
46. Allum WH, Griffin SM, Watson A et al. Guidelines for the management of esophageal and gastric cancer. Gut 2002; 50 (Suppl V): v1-v23
47. Nihei K, Ishikura A, Ohtsu A et al. Long-term survival and toxicity after definitive chemoradiotherapy (CRT) for squamous cell carcinoma (SCC) of the thoracic esophagus. J Clin Oncol 2003; 21: 2697-2702
48. Burmeister BH, Dickie G, Smithers BM et al. Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy. Arch Otolaryngol Head Neck Surg 2000; 126: 205-208
49. Arnott SJ, Duncan W, Gignoux M et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys 1998; 41: 579-583
50. Fok M, Sham JST, Choy D et al. Postoperative radiotherapy for carcinoma of the esophagus: A prospective, randomized controlled trial. Surgery 1993; 113: 138-147
51. Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984
52. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727-1733
53. Kaklamanos IG, Walker GR, Ferry K et al. Neoadjuvant treatment for resectable cancer of the esophagus and gastroesophageal junction: a meta-analysis of randomized trials. Ann Surg Oncol 2003; 10: 754-761
54. Ando N, Lizuka T, Die H et al. A randomized trial of surgery alone vs surgery plus postoperative chemotherapy with cisplatin and 5-fluorouracil for localized squamous carcinoma of the thoracic esophagus: The Japan Clinical Oncology Group Study (JCOG 9204). Proc Am Soc Clin Oncol 1999; 18: 269a
55. Bosset JF, Gignoux M, Triboulet JP et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 1997; 337: 161-167
56. Urschel J, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-543